tesamorelin
Generic: tesamorelin·Brand: Egrifta
tesamorelin: 1 clinical trial tracked.
tesamorelin evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tesamorelin, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)
Primary endpoint: Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points)
InterventionalRandomizedsingle120 targetStarted 2026-02Completion 2028-021 site · ChinaHudson Biotech